-+ 0.00%
-+ 0.00%
-+ 0.00%

Changes in Hong Kong stocks | Xuanzhu Bio-B (02575) rose more than 5% in early trading, new indications for piroxil included in the national basic medical insurance drug catalogue

Zhitongcaijing·11/16/2026 01:41:01
Listen to the news

The Zhitong Finance App learned that Xuanzhu Bio-B (02575) rose more than 5% in early trading. As of press release, it had risen 4.96% to HK$8.675, with a turnover of HK$3.164,400.

According to the news, on November 15, Xuanzhu Bio-B announced that the new indications for the innovative drug piroxilil tablets independently developed by the company, combined with an aromatase inhibitor (AI) for first-line treatment of patients with advanced hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer, have been included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2026)”. The 2026 national basic medical insurance drug catalogue will be officially implemented on January 1, 2027. As of the date of this announcement, all three indications approved by piroxil in mainland China have been included in the national basic medical insurance drug catalogue.

The board of directors believes that this inclusion will further expand the potential beneficiaries of pirosilil tablets, help accelerate their admission to hospitals and clinical application, thereby promoting the commercialization process of pirosilil tablets and further consolidating the Group's competitive advantage in the field of HR+/HER2- advanced breast cancer treatment.